Digital Millennium Copyright Act

To Seek Media LLC (“Company”) has adopted the following policy for copyright infringement in accordance with the Digital Millennium Copyright Act.

If you believe that any content posted on this website infringes on your copyright,
please submit a copyright infringement notification to copyright@toseekmedia.com (see Procedure for Reporting Copyright Infringement below).

Photos

Photos that we upload to this website are public domain images that are licensed under a creative commons zero license. These images are sourced from websites that allow images to be used for free for commercial and noncommercial use where no attribution is required and giving credit to the photographer is not required. When possible, we credit the website from which these photos were downloaded as “Photo” at the end of each article.

If you find that we posted your photo without proper credit, please contact us and we will either delete the photo or credit it properly per your request.

Infringement Claims

All images, photos, and videos on Company’s website are available in various places on the Internet and believed to be in the public domain.

All images, photos, content, and videos on this website are property of their respective owner(s) and images, photos, and videos posted are believed to be posted within our rights according to the U.S. Copyright Fair Use Act (title 17, U.S. Code.)

If you find an image, photo, video, data, material or content that you have rights to on this site, please contact us and we will remove the infringing material as quickly as possible or give you and your website credit for the material(s).

Notices should only be submitted by the copyright owner or an agent authorized to act on the owner’s behalf. Please consider whether fair use, fair dealing or another applicable exception to copyright infringement applies before you make your submission.

Procedure for Reporting Copyright Infringement

Please send the following information:

1) Your full name, address, telephone number, and e-mail address.
2) Identification and a description of the copyrighted work that you claim has been infringed.
3) The URL, location and description of each of the infringing materials that the copyright owner seeks to have removed.
4) A statement, made under the penalty of perjury, that you have a good faith belief that the disputed use has not been authorized by you, your agent, or the law.
5) Your electronic or physical signature or the signature of the person authorized to act on your behalf.

Action Take by the Company

Once proper infringement notification is received by the designated agent, the Company will do the following:

1) Remove the infringing material.
2) Notify the content provider or user via their email that the Company has on file that the Company has removed the material.

Under Section 512(f) of the Copyright Act any person who knowingly materially misrepresents that material or activity is infringing may be subject to liability.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap